Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 875 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV... October 8, 2019 Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in... March 14, 2024 Bagel Shop Owner Shaves Head To Support 10-Year-Old Customer October 27, 2021 Opinion: “There’s cause for optimism in 2021 and beyond” December 30, 2020 Load more HOT NEWS FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated...
